Following NCPE assessment of the company sumbission, reimbursement of Vedolizumab (Entyvio®) is not recommended at submitted price.
Following NCPE assessment of the company sumbission, reimbursement of Vedolizumab (Entyvio®) is not recommended at submitted price.
The cost effectiveness of ibrutinib (Imbruvica®) in the treatment of patients with relapsed or refractory MCL has not been demonstrated. Therefore it is not recommended for reimbursement at the submitted price.
The cost effectiveness of Ibrutinib (Imbruvica®) in the treatment of patients with CLL has not been demonstrated and therefore it is not recommended for reimbursement at the submitted price.
The NCPE concludes that the cost effectiveness of the 5% lidocaine plaster has not been demonstrated.
Reimbursement Not Recommended at submitted price
Following NCPE assessment of the company submission, omalizumab (Xolair ®) is not considered cost-effective for the treatment of severe allergic asthma and therefore is not recommended for reimbursement.
Reimbursement Not Recommended at the submitted price.
Reimbursement recommended for certain subgroups
The NCPE does not recommend reimbursement of Insulin Degludec (Tresiba®) for Type 1 and 2 Diabetes mellitus at the submitted price.